Ascendis Pharma A/S
Research Ascendis Pharma A/S (ASND) on Bullrun: valuation model: 96.4% undervalued, market cap USD 16.29B, P/E 29.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerASND
- ExchangeNASDAQ
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal96.4% undervalued
- Market capUSD 16.29B
- P/E29.7
- Financial periodQ1 2026
- RevenueUSD 246.60M
- Net incomeUSD 629.34M
- Free cash flow-USD 7.72M
- Gross margin92.9%
Valuation Snapshot
Bullrun's latest valuation model marks Ascendis Pharma A/S as 96.4% undervalued; latest market cap is USD 16.29B; P/E is 29.7.
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Frequently asked questions
Is Ascendis Pharma A/S overvalued or undervalued?
Bullrun's valuation model currently marks Ascendis Pharma A/S as 96.4% undervalued.
What is Ascendis Pharma A/S's market cap?
Ascendis Pharma A/S's market capitalization is USD 16.29B.
What is Ascendis Pharma A/S's P/E ratio?
Ascendis Pharma A/S's price-to-earnings (P/E) ratio is 29.7.
What does Ascendis Pharma A/S do?
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency;